BYOT.L Regulatory News (BYOT)

16th April 2015

Byotrol plc

("Byotrol" or the "Company)

TRADING UPDATE

The Board is pleased to report a year of good progress, with the professional and petcare segments performing particularly well. Consumer, after non-recurring items, has held up well as we introduce new technologies into the market. We are confident that consumer revenues will pick up in the next financial year, including in the United States as we continue to work our way through the US regulatory (EPA) process (as previously reported).

The Board is expecting sales for the year to 31 March 2015 to be in the region of £3.2 million and the loss before interest taxation and depreciation to be approximately £425k. In the prior year, after allowing for non-recurring items, sales to 31 March 2014 were £2.75m and the loss before interest taxation and depreciation was £1.1m.

We continue to invest heavily in R&D, having invested well over £400k in the year. Much of this spend has been devoted to updating our technologies in preparation for the new EU regulatory regime for biocides. This has involved considerable re-formulation work to our core range, work which is progressing very well but is ongoing. We have recently been granted a patent for our new consumer surface care product and have filed a patent for a new skincare technology which we believe has significant potential across our whole business.

We remain committed to a strategy of product development to increase sales and expect to achieve monthly break even in the latter half of the current financial year.

We have also been developing new commercial partnerships, particularly with larger companies that can offer us good distribution and complementary technical expertise. We have reached heads of agreement with various parties, including a joint marketing agreement with ISS Facility Services - Healthcare ("ISS"), which is part of the ISS group, one of the world's largest facility services providers. In this deal we will be working with ISS to target surface care opportunities in the UK NHS. This and other commercial partnerships will enable us to reach more and larger customers than we might manage on our own and we expect to be announcing further details on this and other deals over the next few months.

This is an exciting time for Byotrol and we have both the technology and opportunity to achieve significant growth as we continue to move towards profitability. The Company intends to release its unaudited Preliminary Results for the year to 31st March 2015 in early June and to hold our AGM on 28th July, 2015.

Enquiries:

Notes to Editors:

Byotrol plc (BYOT.L), quoted on AIM, is a leading anti-microbial technology company, operating globally in the Food, Industrial, Healthcare and Consumer sectors, providing a low toxicity products with a broad-based and long-lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, mycobacteria and algae.

Powerful, long-lasting and gentle, Byotrol's products can be used stand alone or as an ingredient within existing products, where Byotrol can significantly improve their performance in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

Founded in 2005, the Company has developed the technology that creates easier, safer and cleaner lives for everyone.

For more information, please go to www.byotrol.co.uk